Recent Research Funding

John Canty and Amanda Ribbeck

“Our faculty have great success securing competitive grants that allow us to further our innovative research,” says John Canty Jr., division chief, with fellow Amanda Ribbeck.

We receive funding from a variety of sources that recognize the value of our high-impact research.

With the support of government agencies, foundations, institutes and industry, our faculty make significant contributions to patient health and our understanding of cardiovascular disease.

We’ve been awarded grants from numerous funding sources, including:

  • National Institutes of Health
  • American Heart Association
  • Veterans Health Administration

Some of our recent research efforts, listed by faculty investigator, are as follows:

John Canty, Jr., MD

  • National Heart Lung and Blood Institute, UB Clinical Scholar Program in implementation science to achieve triple aims. John Canty, Jr. (Co-Principal Investigator), Ranjit Singh (Co-Principal Investigator). National Heart Lung and Blood Institute. 9/1/2017-8/1/2022.
  • Prediction of Arrhythmic Events with Positron Emission Tomography - II (PAREPET II). John Canty, Jr. (Co-Principal Investigator), James Fallavollita (Co-Principal Investigator). National Heart Lung and Blood Institute - NHLBI. $3,726,616. 11/1/2016-12/1/2021.
  • Clinical Translational Science Award (CTSA). John Canty, Jr. (Co-Principal Investigator), Margarita Dubocovich (Principal Investigator), Peter Elkin (Co-Investigator), Leonard Epstein (Co-Investigator), Steven Fliesler (Co-Investigator), Alan Hutson (Co-Investigator), Gene Morse (Co-Investigator), Sanjay Sethi (Co-Investigator), Laurene Tumiel Berhalter (Co-Investigator). National Institutes of Health. $16,000,000. 1/1/2016-1/1/2019.
  • VA Merit Review, Dynamic remodeling from reversible ischemia and sudden cardiac arrest. John Canty, Jr. (Co-Investigator). VA. $649,600. 1/1/2016-12/1/2019.
  • Prediction ARrhythmic Events with Positron Emission Tomography - II (PAREPET-II). John Canty, Jr. (Co-Principal Investigator), James Fallavollita (Co-Principal Investigator). NIH - NHLBI. 1/1/2016-12/1/2021.
  • Self-replicating RNA-nanoplexes for Programming Monocytes to Regenerate the Heart. John Canty, Jr. (Co-Investigator), Juliane Nguyen (Principal Investigator). National Heart Lung and Blood Institute. $432,013. 7/1/2015-6/1/2017.
  • Mechanisms of cKit+ Cardiac Stem Cell-Mediated Repair in Ischemic Cardiomyopathy. John Canty, Jr. (Principal Investigator), Gen Suzuki (Co-Investigator). National Heart Lung and Blood Institute. $2,056,476. 11/1/2014-10/1/2018.
  • T3-Nanformulation Evaluation in Preparation for Clinical Trials. John Canty, Jr. (Principal Investigator), Gen Suzuki (Co-Investigator). UB Cat. 1/1/2013-12/1/2018.
  • Biomarker Release after Reversible Ischemia. John Canty, Jr. (Co-Investigator), Jun Qu (Principal Investigator). American Heart Association. $385,000. 1/1/2011-12/1/2015.

Thomas Cimato, MD, PhD

  • Center for AIDS Research Pilot Grant. Thomas Cimato (Co-Principal Investigator). NIH/NIAID, University of Rochester CFAR. $15,350. 4/1/2017-3/1/2018.
  • The Mae Stone Goode Charitable Trust. Thomas Cimato (Principal Investigator), Brahm Segal (Co-Principal Investigator). $100,000. 3/1/2016-3/1/2019.
  • National Institutes of Health/NIDCR:Effect of COMT genetic polymorphisms on response to propranolol therapy in TMD. Thomas Cimato (Co-Investigator). National Institutes of Health/NIDCR. 9/1/2014-8/1/2017.
  • Clinical Trial: Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). Thomas Cimato (Co-Investigator). Novartis Pharmaceuticals. 6/1/2014-1/1/2018.

John Corbelli, MD

  • VA Cooperative Study # 578 Prevention of Serious Adverse Events Following Angiography (PRESERVE). John Corbelli (Principal Investigator). Veterans Health Administration. $432,000. 1/1/2016-1/1/2021.

Anne Curtis, MD

James Fallavollita, MD

  • Prediction of Arrhythmic Events with Positron Emission Tomography - II (PAREPET II). James Fallavollita (Co-Principal Investigator), John Canty, Jr. (Co-Principal Investigator). National Heart Lung and Blood Institute - NHLBI. $3,726,616. 11/1/2016-12/1/2021.
  • Prediction ARrhythmic Events with Positron Emission Tomography - II (PAREPET-II). James Fallavollita (Co-Principal Investigator), John Canty, Jr. (Co-Principal Investigator). NIH - NHLBI. 1/1/2016-12/1/2021.
  • Dynamic Remodeling From Reversible Ischemia and Sudden Cardiac Arrest. James Fallavollita (Co-Investigator), Jun Qu (Co-Principal Investigator). Department of Veterans Affairs. 10/1/2015-9/1/2019.

Jennifer Lang, MD

  • VA CDA-2, The Functional Role of Exosomes in Stem Cell-Mediated Cardiac Repair, VA. Jennifer Lang (Principal Investigator). Veteran‘s Administration. $1,389,635. 10/1/2018-9/1/2023.
  • The Functional Role of Exosomes in Stem Cell Mediated Cardiac Repair. Jennifer Lang (Principal Investigator). NIH/NHLBI. $1,006,430. 12/1/2017-11/1/2022.

Umesh Sharma, MD, PhD

  • Activating Adrenergic Receptors to Suppress the Anti-graft Immune Response and Improve Survival of Composite Tissue Allografts. Umesh Sharma (Co-Investigator). National Institutes of Health/SBIB. $356,467. 7/1/2018-6/1/2020.
  • Liposomal Delivery of a Novel Peptide N-Acetyl-Ser-Asp-Lys-Pro to Inhibit Cancer Radiotherapy-Induced Cardiac Damage. Umesh Sharma (Co-Investigator). National Institutes of Health/NHLBI. $462,000. 4/1/2018-2/1/2020.
  • National Institutes of Health/NHLBI, K08. Umesh Sharma (Principal Investigator). NHLBI. $986,850. 7/1/2017-6/1/2022.

Gen Suzuki, MD, PhD

  • UB IMPACT, 3D bioengineered cell sheet for cardiac. Gen Suzuki (Principal Investigator). University at Buffalo. 1/1/2017-1/1/2018.
  • NIH National Heart Lung and Blood Institute, Mechanisms of cKit Cardiac Stem Cell-Mediated Repair in Ischemic Cardiomyopathy. Gen Suzuki (Co-Investigator). NIH National Heart Lung and Blood Institute. 11/1/2014-11/1/2019.
  • Mechanisms of cKit+ Cardiac Stem Cell-Mediated Repair in Ischemic Cardiomyopathy. Gen Suzuki (Co-Investigator), John Canty, Jr. (Principal Investigator). National Heart Lung and Blood Institute. $2,056,476. 11/1/2014-10/1/2018.
  • T3-Nanformulation Evaluation in Preparation for Clinical Trials. Gen Suzuki (Co-Investigator), John Canty, Jr. (Principal Investigator). UB Cat. 1/1/2013-12/1/2018.